HRMY vs. CPRX, EVO, SDGR, SUPN, GPCR, AGIO, ZLAB, AVDL, GLPG, and NAMS
Should you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Catalyst Pharmaceuticals (CPRX), Evotec (EVO), Schrödinger (SDGR), Supernus Pharmaceuticals (SUPN), Structure Therapeutics (GPCR), Agios Pharmaceuticals (AGIO), Zai Lab (ZLAB), Avadel Pharmaceuticals (AVDL), Galapagos (GLPG), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
Catalyst Pharmaceuticals (NASDAQ:CPRX) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
Harmony Biosciences has higher revenue and earnings than Catalyst Pharmaceuticals. Harmony Biosciences is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Catalyst Pharmaceuticals currently has a consensus target price of $26.71, indicating a potential upside of 67.59%. Harmony Biosciences has a consensus target price of $40.63, indicating a potential upside of 34.79%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Harmony Biosciences.
Catalyst Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
In the previous week, Catalyst Pharmaceuticals had 11 more articles in the media than Harmony Biosciences. MarketBeat recorded 15 mentions for Catalyst Pharmaceuticals and 4 mentions for Harmony Biosciences. Catalyst Pharmaceuticals' average media sentiment score of 1.75 beat Harmony Biosciences' score of 0.34 indicating that Harmony Biosciences is being referred to more favorably in the news media.
Catalyst Pharmaceuticals received 442 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 74.31% of users gave Catalyst Pharmaceuticals an outperform vote while only 60.29% of users gave Harmony Biosciences an outperform vote.
Harmony Biosciences has a net margin of 22.30% compared to Harmony Biosciences' net margin of 15.83%. Catalyst Pharmaceuticals' return on equity of 28.26% beat Harmony Biosciences' return on equity.
Summary
Catalyst Pharmaceuticals and Harmony Biosciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Harmony Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Harmony Biosciences Competitors List
Related Companies and Tools
